我要投票 保灵药业在中草药行业中的票数:503
· 外 推 电 报 ·
2025-09-22 07:37:37 星期一

【保灵药业是哪个国家的品牌?】

保灵药业是什么牌子?「保灵药业」是 杭州澳医保灵药业有限公司 旗下著名品牌。该品牌发源于浙江,由创始人钟海荣在1994-12-30期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力保灵药业品牌出海!将品牌入驻外推网,定制保灵药业品牌推广信息,可以显著提高保灵药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

杭州保灵集团有限公司,成立于1985年,是国内较早从事蜂产品深度研究开发生产的企业。2013年8月,保灵集团正式牵手山西仟源制药股份有限公司。

澳医保灵成立于1994年,由保灵集团与澳大利亚、新加坡合资组建,注册资本为2882.47万元,位于杭州市保灵路5号,主要经营药品与原料药的生产工作。先后被评为杭州市高新技术企业及浙江省高新技术企业。

浙江保灵成立于2006年,由保灵集团与爱美雅(新加坡)有限公司合资组建,注册资本为8800万元,位于杭州经济技术开发区23号大街668号。一期总投资1.6亿元的现代化药品保健食品制造基地,于2010年12月投产。2013年12月,澳医保灵吸收合并浙江保灵。吸收合并后,浙江保灵于工商注销,澳医保灵注册资本为8800万元,注册地址为杭州经济技术开发区23号大街668号。

保灵药业主要从事药品、保健食品、蜂产品、植物提取物的研发、生产和销售。公司是国内著名的孕妇健康产品生产商和供应商,其系列产品包括保灵孕宝口服液、保灵孕妇钙咀嚼片、保灵孕多维片以及保胎无忧片、生乳片等,其中保灵孕宝口服液自1989年(与澳方合资前由中方公司生产)上市以来,深受广大医生和孕妇的喜爱,“怀孕了就喝保灵孕宝”,“保灵孕宝健康两代人”已经深入人心。公司还拥有抗过敏药物,国家二类新药---依巴斯汀片(商品名“思金”),治疗青光眼药物---醋甲唑胺片(商品名“尼目克司”)等市场优势品种。自1997年以来,“保灵”商标就被评为浙江省著名商标。

保灵药业视产品质量为企业的立足之本,更是企业对社会的一种责任。公司每年按销售额的一定比例拨出专项资金作为技术改造及新产品研发费用,不断引进国内外领先的先进生产研发设备,如高效液相色谱仪、红外分光光度计等等,提高工作效率,改善生产条件,确保了产品质量安全稳定。保灵药业是浙江省首批通过药品和保健食品GMP双认证的企业。

保灵药业拥有一支高素质的员工队伍。在现有员工中,各类专业技术人员的比例超过40%。公司非常重视企业文化建设,不断引进现代企业管理理念和方法。培育了“效率、效益、和谐发展”为特质的保灵文化,培养了具有“忠诚、友善、敬业、创新”精神的保灵人。在和谐的保灵大家庭中,广大员工视公司为家,涌现了包括全国劳模、省劳模在内的一大批优秀人才。近年来,公司先后被评为浙江省文明单位、杭州市模范集体、杭州市和谐劳动关系先进企业、浙江省先进技术企业,浙江省高新技术企业,省级研发中心,杭州市工业重点纳税企业。

英文翻译:Hangzhou Baoling Group Co., Ltd., founded in 1985, is one of the earliest domestic enterprises engaged in the in-depth research, development and production of bee products. In August 2013, Baoling group formally joined hands with Shanxi Qianyuan Pharmaceutical Co., Ltd. Founded in 1994 by Baoling group, Australia and Singapore, aowuling has a registered capital of 28.8247 million yuan and is located at No.5, Baoling Road, Hangzhou, mainly engaged in the production of drugs and APIs. It has been awarded as Hangzhou high tech enterprise and Zhejiang high tech enterprise successively. Zhejiang Baoling was founded in 2006 by Baoling group and aimiya (Singapore) Co., Ltd. with a registered capital of 88 million yuan, it is located at No. 668, No. 23 street, Hangzhou Economic and Technological Development Zone. The first phase of a modern pharmaceutical and health food manufacturing base with a total investment of 160 million yuan was put into production in December 2010. In December 2013, aomaling absorbed and merged with Zhejiang Baoling. After the merger, Zhejiang Baoling was cancelled by industry and commerce. The registered capital of aobaoling is 88 million yuan, and the registered address is No. 668, No. 23 street, Hangzhou Economic and Technological Development Zone. Baoling pharmaceutical is mainly engaged in the R & D, production and sales of drugs, health food, bee products and plant extracts. The company is a famous manufacturer and supplier of pregnant women's health products in China. Its series of products include baolingyunbao oral liquid, Baoling pregnant women's calcium chewable tablets, baolingyun multi-dimensional tablets, baofetal worry free tablets, raw milk tablets, etc., among which baolingyunbao oral liquid has been popular with doctors and pregnant women since it was launched in 1989 (before the joint venture with Australia, it was produced by a Chinese company), and "drink when pregnant" "Baoling pregnant treasure" and "Baoling pregnant treasure healthy two generations" have been deeply rooted in people's hearts. The company also has anti allergy drugs, national class II new drugs - ebastine tablets (trade name "sikin"), glaucoma drugs - acetazolamide tablets (trade name "nemex") and other market advantages. Since 1997, "Baoling" trademark has been awarded as a famous trademark in Zhejiang Province. Baoling pharmaceutical regards product quality as the foundation of the enterprise, and it is also a responsibility of the enterprise to the society. According to a certain proportion of the sales volume, the company allocates special funds every year as the cost of technological transformation and new product research and development, and constantly introduces advanced production and research and development equipment at home and abroad, such as high-performance liquid chromatograph, infrared spectrophotometer, etc., to improve work efficiency, improve production conditions, and ensure the safety and stability of product quality. Baoling pharmaceutical is one of the first enterprises in Zhejiang Province to pass the GMP double certification of drugs and health food. Baoling pharmaceutical has a high-quality staff. In the existing staff, the proportion of all kinds of professional and technical personnel is more than 40%. The company attaches great importance to the construction of enterprise culture and constantly introduces modern enterprise management concepts and methods. It has cultivated a spirit preserving culture characterized by "efficiency, efficiency and harmonious development", and a spirit of "loyalty, friendliness, dedication and innovation". In the harmonious Baoling family, the majority of employees regard the company as their home, and a large number of outstanding talents including national and provincial model workers have emerged. In recent years, the company has been rated as a civilized unit in Zhejiang Province, a model collective in Hangzhou, an advanced enterprise in harmonious labor relations in Hangzhou, an advanced technology enterprise in Zhejiang Province, a high-tech enterprise in Zhejiang Province, a provincial R & D center, and a key industrial tax paying enterprise in Hangzhou.

本文链接: https://www.waitui.com/brand/940fa6127.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

山西汾酒:股东华创鑫睿计划减持不超1.33%公司股份

36氪获悉,山西汾酒发布公告,根据联和基金相关合作协议,其面临基金到期退出安排,需要减持其间接持有的全部公司股份,因此持股5%以上股东华创鑫睿本次拟通过大宗交易方式减持不超过1620.06万股(含本数),计划减持比例不超过1.33%;自本次减持计划公开披露之日起15个交易日后的3个月内(含3个月期满当日)实施。

2小时前

中信证券:三方面的技术趋势将推动刻蚀设备的用量和重要性提升

36氪获悉,中信证券预计,至少以下三方面的技术趋势将推动刻蚀设备的用量和重要性提升:1.光刻多重图案化路线的采用;2.三维堆叠存储和近存计算需求;3.底层晶体管结构升级。长期看,半导体设备国产化方向明确,短期来看,下游扩产有望驱动行业进入新一轮增长期。建议关注国内刻蚀设备厂商以及相关配套设备、零部件企业机会。

2小时前

中信证券:右侧趋势品种继续聚焦资源、消费电子、创新药和游戏

36氪获悉,中信证券研报表示,目前整体的行业选择框架依然是围绕资源+新质生产力+出海。资源股在供给受限以及全球地缘动荡的预期推动下,从周期属性转向偏红利属性会带来估值体系重构,博弈美联储降息的资金退潮带来的波动可以忽略。更大的中期线索还是中国制造业龙头的全球化,将份额优势转化为定价权和利润率提升,带来超越本国经济基本面的市值增长,从而逐步打破行情与基本面背离且全靠流动性驱动的错误认知。配置结构上,保持定力,右侧趋势品种继续聚焦资源、消费电子、创新药和游戏;左侧配置关注化工和军工;产业趋势层面,近期重点关注AI从云侧逻辑开始向端侧逻辑扩散。

2小时前

环球印务:股东香港原石拟减持不超1%公司股份

36氪获悉,环球印务发布公告,持股10.98%的股份的股东香港原石国际有限公司(简称“香港原石”)计划以集中竞价交易合计减持不超过320.04万股公司股份,占公司总股本比例的1%。

2小时前

冠中生态:筹划控制权变更事项,股票停牌

36氪获悉,冠中生态发布公告,公司控股股东青岛冠中投资集团有限公司及实际控制人李春林和许剑平正在筹划公司控制权变更相关事宜,可能导致公司控股股东及实际控制人发生变更。经申请,公司股票及可转换公司债券自2025年9月22日起停牌,预计停牌时间不超过2个交易日。停牌期间,公司可转换公司债券“冠中转债”将暂停转股。

2小时前

本页详细列出关于保灵药业的品牌信息,含品牌所属公司介绍,保灵药业所处行业的品牌地位及优势。
咨询